First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun Vasant Balar(NYU Langone Health), Joaquim Bellmunt(Dana-Farber Cancer Institute), Lei Pang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Daniel Castellano(Universidad Complutense de Madrid), Petros Grivas(Seattle Cancer Care Alliance), Elizabeth R. Plimack(Fox Chase Cancer Center), Ronald de Wit(Erasmus MC Cancer Institute), Stephen J. O’Keefe(University of Pittsburgh), Dean F. Bajorin(Memorial Sloan Kettering Cancer Center), Rodolfo F. Perini(Merck & Co., Inc., Rahway, NJ, USA (United States)), Thomas Powles(Queen Mary University of London), Jacqueline Vuky(Oregon Health & Science University), Noah M. Hahn(Johns Hopkins University), Mary J. Savage(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter H. O’Donnell(University of Chicago)
Cited by 1,341
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k